Sequence Bio
Lynn Healey is the current CEO at Sequence Bio, where they are focused on discovering true signals of disease to power life-changing medicines. Prior to joining Sequence Bio, Lynn served as the Chief Investment Officer at Teachers' Pension Plan Corporation and held various roles at Ernst & Young, including Partner and Senior Manager. Lynn holds a Bachelor of Commerce degree in Accounting and Finance from Memorial University of Newfoundland.
This person is not in any teams
Sequence Bio
90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.